EZH2 inhibition overcomes immune evasion in lung adenocarcinoma by restoring CCL5-mediated T-cell recruitment and MHC class I antigen presentation
Acta Biochimica et Biophysica Sinica · 01.03.2026
DOI: 10.3724/abbs.2026013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Biochimica et Biophysica Sinica, online erschienen am 03.03.2026. Verfasst von Qinuo Lin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
Immunotherapy represents a pivotal advancement in lung cancer treatment. However, its efficacy remains limited, necessitating a deeper understanding of intrinsic tumor cell mechanisms that modulate the immune microenvironment. Here, we investigate how EZH2 inhibition alters chemokine secretion and antigen presentation in lung adenocarcinoma (LUAD). TCGA and GEO analyses show significant overexpression of EZH2 in LUAD, which correlates with poorer survival. Immune cell infiltration using MCP-Counter demonstrates that EZH2 expression inversely correlates with CD8 + T cell and dendritic cell (DC) infiltration. Spatial analysis of early lung cancer samples reveals an inverse EZH2-CCL5 correlation, suggesting that EZH2 promotes progression via CCL5 suppression. In vitro assays included CCK-8 proliferation assays following EZH2 inhibition, qRT-PCR and ELISA to quantify CCL5 expression and secretion, transwell migration assays to assess CD8 + T-cell chemotaxis, and co-culture cytotoxicity assays to evaluate MHC class I-dependent T-cell killing. Inhibition of EZH2 markedly reduces tumor cell proliferation, increases CCL5 expression and secretion, enhances CD8 + T-cell migration, and promotes MHC class I expression and T-cell-mediated cytotoxicity without altering PD-L1 levels. In conclusion, EZH2 overexpression promotes immune evasion in LUAD by suppressing CCL5-mediated T-cell recruitment and MHC class I antigen presentation. Targeting EZH2 augments antitumor immunity, supporting its therapeutic potential in combination immunotherapy strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Zitieren
APA
Lin, Q., Wu, F., Zhang, L., Zhang, Y., Sun, S., Wu, X., & Yu, H. (2026). EZH2 inhibition overcomes immune evasion in lung adenocarcinoma by restoring CCL5-mediated T-cell recruitment and MHC class I antigen presentation. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2026013
Vancouver
Lin Q, Wu F, Zhang L, Zhang Y, Sun S, Wu X, et al. EZH2 inhibition overcomes immune evasion in lung adenocarcinoma by restoring CCL5-mediated T-cell recruitment and MHC class I antigen presentation. Acta Biochimica et Biophysica Sinica. 2026. doi:10.3724/abbs.2026013
BibTeX
@article{Lin2026,
author = {Lin, Qinuo and Wu, Fangtian and Zhang, Lanlin and Zhang, Yao and Sun, Si and Wu, Xianghua and Yu, Hui},
title = {EZH2 inhibition overcomes immune evasion in lung adenocarcinoma by restoring CCL5-mediated T-cell recruitment and MHC class I antigen presentation},
journal = {Acta Biochimica et Biophysica Sinica},
year = {2026},
doi = {10.3724/abbs.2026013}
}
EUVIMED